In the present study, a series of novel pyrimidines (1) and their thioethers (2-5) were synthesized. Structures of the synthesized compounds were established by IR, 1 H NMR, 13 C NMR mass spectral data and elemental analysis. All the newly synthesized compounds were screened for their in vitro antibacterial and antifungal activities. Among the compounds tested, few were found to be most effective antibacterial and antifungal agents. The Structure-activity relationship studies revealed that thiazolopyrimidine derivatives carrying 3-nitrophenyl (4c) or 4-hydroxyphenyl (4b) group exhibited highest antibacterial activity, whereas dimethylated adduct carrying 3-nitrophenyl (2c) group exhibited highest antifungal activity. The results revealed that the synthesized compounds may be a potential lead for future drug discovery.
Introduction
Pyrimidine, being an integral part of DNA and RNA, imparts diverse pharmacological properties such as effective bactericide and fungicide. 1, 2 Certain pyrimidine derivatives are also known to possess antimalarial, 3 antifilarial, 4 antibacterial, antifungal, 5,6 anticonvulsant 7 and antihistamine 8 activities. Some of the 3,4-dihydropyrimidines (DHPM) have emerged as integral backbones of several calcium channel blockers, antihypertensive agents, adrenergic and neuropeptide antagonist. 9 Several natural marine products containing the 3,4-dihydropyrimidine core have been reported in the literature with interesting biological activities such as the anti-HIV alkaloid batzelladine B. 10, 11 Fused pyrimidine derivatives have attracted attention of numerous researchers over many years, due to their important biological activities. Preclinical data from literature survey indicated that the heterocycles in association with the pyrimidine have shown good antimicrobial, [12] [13] [14] antioxidant, 14 antitumour, 15 analgesic, anti-inflammatory 16, 17 and antipyretic 17 activities. In particular, bezimidazolo-pyrimidine 18, 19 and thiazolo-pyrimidine [20] [21] [22] [23] derivatives were found as potent antimicrobial agents ( Fig. 1) .
Motivated by the above mentioned findings and in continuation of our investigation, 24 to discover new potentially active agents, we have synthesized some new pyrimidines (1) and their thioethers (2) (3) (4) (5) . All the newly synthesized compounds were characterized by spectroscopic techniques and evaluated for their in vitro antibacterial and antifungal activities.
Experimental
Unless otherwise noted, materials were obtained from commercial suppliers and used without further purification. Melting points were determined by Micro control based melting point instrument and are uncorrected. All reactions were monitored by thin-layer chromatography on 0.25 mm silica gel (60GF-254) plates, using ethyl acetate:butanol:chloroform in the ratio of [1:2:1] as mobile phase and visualized with UV light. Column chromatography was performed on silica gel (200-300 mesh). Infra red (IR) spectra were recorded by using KBr pellet on a Thermo Nicolate IR-400 FTIR spectrophotometer, 1 H NMR spectra were recorded on Bruker Avance-400F spectrometer (400 MHz) using tetramethylsilane as internal standard (chemical shift in d ppm) and LC-MS with Waters Micromass Q-Tof Micro. To a mixture of the selected aryl aldehyde (50 mmol) and thiourea in absolute ethanol (50 ml), ethyl cyanoacetate (5.7 g, 50 mmol) and potassium carbonate (6.9 g, 50 mmol) were added. The reaction mixture was heated under reflux until completion of the reaction, and then neutralized with glacial acetic acid. The separated solid product was filtered, dried and crystallized from suitable solvents. To a solution of the selected 1a-d (20 mmol) in dimethylformamide (DMF, 30 ml), methyl iodide (5.68 g, 40 mmol) and potassium carbonate (5.52 g, 40 mmol) were added. The reaction mixture was stirred at room temperature until completion of the reaction. The reaction mixture was then diluted with ice cold water and neutralized with glacial acetic acid. The separated solid product was filtered, dried and crystallized from DMF/water. 
To a solution of the selected 1a-d (20 mmol) in DMF (30 ml), benzyl chloride (2.53 g, 20 mmol) and potassium carbonate (2.76 g, 20 mmol) were added. The reaction mixture was stirred at room temperature until completion of the reaction. The reaction mixture was then diluted with ice cold water and neutralized with glacial acetic acid. The separated solid product was filtered, dried and crystallized from DMF/water. 
To a solution of the selected 1a-c (20 mmol) in DMF (30 ml), 1,2-dichloroethane (1.98 g, 20 mmol) and potassium carbonate (2.76 g, 20 mmol) were added. The reaction mixture was stirred at room temperature until completion of the reaction. The reaction mixture was then diluted with ice cold water and neutralized with glacial acetic acid. The separated solid product was filtered, dried and crystallized from DMF/water. (3. 33 g, 20 mmol) in DMF was then added portion wise and the reaction mixture was stirred at room temperature until completion of the reaction. Then the reaction mixture was poured onto crushed ice with stirring. The separated solid product was filtered, dried and crystallized from DMF/water. 
Antimicrobial activity

In vitro antibacterial activity
The antibacterial activity of the synthesized compounds was determined against Gram-positive bacteria (Bacillus subtilis and Staphylococcus aureus) and Gram-negative bacteria (Pseudomonas aeruginosa and Escherichia coli) in DMF by disc diffusion method using nutrient agar as medium. 25 The sterile medium (Nutrient Agar Medium, 15 ml) in each petri plate was uniformly smeared with cultures of Gram-positive and Gram-negative bacteria. Sterile discs of 6 mm diameter were placed in the petri plates, to which 100 ll solution of synthesized compounds in DMF at different concentrations such as 250, 500 and 1000 lg/ml (25, 50, 100 lg/disc) was added. The treatment also included 100 ll of DMF as negative control and Streptomycin as positive control 26 for comparison. The plates were incubated at 37 ± 2°C for 24-48 h and the zone of inhibition was determined.
In vitro antifungal activity
All the synthesized compounds were screened for their antifungal activity against Aspergillus niger and Candida albicans in DMF by the disc diffusion method. 25 The sterile medium (Potato Dextrose Agar Medium, 15 ml) in each petri plate was uniformly smeared with cultures of fungi. Sterile discs of 6 mm diameter were placed in the petri plates, to which 100 ll solution of synthesized compounds in DMF at different concentrations such as 250, 500 and 1000 lg/ml (25, 50, 100 lg/disc) was added. The treatment also included 100 ll of DMF as negative control and amphotericin B as positive control 27, 28 for comparison. The plates were incubated at 26 ± 2°C for 48-72 h and the zone of inhibition was determined.
Antibacterial and antifungal activity (Minimum inhibitory concentration) by serial dilution method
The minimum inhibitory concentration of the compounds was determined in Nutrient broth (NB) for bacteria and in Sabourauds dextrose broth (SDB) for fungi by the serial dilution method. [29] [30] [31] Seeded broth (broth containing microbial spores) was prepared in NB from 24 h old bacterial cultures on nutrient agar (Hi-media, India) at 37 ± 1°C, whereas fungal spores from 24 h to 7 days old Sabourauds agar slant cultures were suspended in SDB. The bacterial suspension was adjusted with sterile saline to a concentration of 1 · 10 4 -10 5 CFU. The compounds (1-5) were screened for their antibacterial and antifungal activities in triplicate sets at different concentrations (1000, 500, 250 and 200 lg/mL). The compounds which were found to be active in primary screening were further diluted to obtain 100, 50, and 25 lg/mL concentrations. The tubes were incubated in BOD incubators at 37 ± 1°C for bacteria and 28 ± 1°C for fungi. The minimum inhibitory concentration (MIC) was recorded by visual observation after 24 h (for bacteria) and 72-96 h (for fungi) of incubation. The lowest concentration, which show no growth after spot subculture was considered as MIC for each compound. The highest dilution showing at least 99% inhibition was taken as minimum inhibitory concentration (MIC). Streptomycin and Amphotericin B were used as standards for bacterial and fungal study, respectively.
Results and discussion
Chemistry
In the present work, the title compounds, 4-substituted-6-oxo-2-sulphanyl-1,6-dihydropyrimidine-5-carbonitrile (1a-d), were synthesized by potassium carbonate catalysed three-component cyclization of aryl aldehydes, thiourea and ethyl cyanoacetate in ethanol. Stirring of selected 1a-d and methyl iodide in DMF in the presence of potassium carbonate yielded dimethy-lated adduct, 4-(substituted)-1-methyl-2-(methylsulphanyl)-6oxo-1,6-dihydropyrimidine-5-carbonitrile (2a-d) (Scheme 1). The thioether adduct, 4-(substituted)-1-methyl-2-(benzylsulphanyl)-6-oxo-1,6-dihydropyrimidine-5-carbonitrile (3a-d) is also synthesized by stirring selected 1a-d derivatives and benzyl chloride in the presence of potassium carbonate in DMF (Scheme 2). Stirring of selected 1a-c and 1,2-dichloroethane in DMF in the presence of potassium carbonate resulted in cyclization to give 7-(substituted)-5-oxo-2,3-dihydro-5H- [1, 3] 
Spectral elucidation
All the pyrimidine derivatives were synthesized and confirmed by physical data, IR, 1 H NMR and Mass spectral data. Structure of few compounds was also established by 13 C NMR. All the compounds have shown C"N peak in the range of 2228-2206 cm À1 , C‚O peak in the range of 1716-1609 cm À1 , C‚N peak in the range of 1635-1509 cm À1 and C‚C peak in the range of 1553-1414 cm À1 in IR. The phenolic derivatives have shown the OH peak in the range of 3598-3264 cm À1 . The nitro derivatives have shown C-NO 2 peak in the range of 1352-1285 cm À1 . The 1a-d compounds have shown peak in the range of 3431-3316 cm À1 for the N-H stretch in IR, which is absent in 2a-d compounds. The 2a-d, 3a-d, 4a-c and 5a-c compounds have shown CASAC peak in the range of 1178-1094 cm À1 . Compounds, 1a-d, 3a-d and 5a-c have shown peak in the range of 3431-3215 cm À1 for NH.
All the compounds have shown peaks for Ar-H in the range of d 6.74-8.86 in 1 H NMR. All the phenolic derivatives have shown singlets in the range of d 9.31-11.58 for Ar-OH in 1 All the synthesized derivatives have shown M+1 peak in mass spectra except 1c , 1d and 5a compounds, which have shown MÀ1 peak. The IR, 1 H NMR, 13 C NMR and Mass spectral data supported the structure of various synthesized compounds.
Antimicrobial activity
The newly synthesized compounds were screened for their antimicrobial activity against Gram-negative bacteria (Escherichia coli, Pseudomonas aeruginosa), Gram-positive bacteria (Bacillus subtilis and Staphylococcus aureus) and fungi (Candida albicans and Aspergillus niger). The results of preliminary antibacterial and antifungal testing of the compounds were Novel pyrimidines and their thioethers reported as zone of inhibition (Table 1 and Table 2 ) and Minimum inhibitory concentration ( Table 3 ). The results of antibacterial studies revealed that thiazolo-pyrimidines (4a-c) and benzimidazolo-methyl-sulphanyl-pyrimidine (5a-c) derivatives were showing significant antibacterial activity against all the tested strains. Compounds, 2a and 2b are inactive against all the species of bacteria, whereas compounds 2c-d, 3a and 3d are inactive against Gram-positive bacteria. All the other derivatives showed moderate to potent activity against all the bacterial strains. Amongst the derivatives in 1, 3, 4 and 5 series, the 3-nitrophenyl derivatives exhibited potent antibacterial activity. As compared to the standard streptomycin, compounds 4c, 4b, 5c and 4a exhibited good activity against all the tested strains, while compounds 5b, 5a, 1c, 1d, 1b and 3c were moderately active. Compound 4c was found to be most potent against all the species of bacteria. Compounds carrying thiazolo and benzimidazole rings have shown best results as compared to the other derivatives and hence favour the antibacterial activity.
The results of preliminary antifungal testing revealed that compounds 4a, 4b and 3a are inactive against both species of fungi. Compounds 2c, 2d and 5c exhibited potent activity against both the species, while the compounds 2a, 2c, 5a, 5b, 1c, 1d, 1b and 1a exhibited moderate to potent activity. Dimethylated adduct (2a-d) and benzimidazole substituted derivatives (5a-c) have shown best results as compared to the other derivatives.
Structure-activity relationship (SAR) studies
The structure-activity studies showed that depending on the nature of the heterocyclic skeleton and its substituent, the newly synthesized compounds exhibit varying degrees of microbial inhibition. From the in vitro antibacterial screening results, it has been found that the pyrimidines carrying thiazolo (4a-c) and benzimidazole (5a-c) rings have shown better activity as compared to the other derivatives. Within the same series the inhibitory activity depends on the nature of substituent attached to the benzene ring. The antibacterial screening indicated that the presence of 3-nitrophenyl and 4-hydroxyphenyl substitution as in compounds (4c, 4b, 5c, 5b, 1c, 1b, 3c, 3b, 2c and 2b) increased their inhibitory activities compared - 8  9  11  8  10  13  9  11  14  ---3c  10  14  16  9  14  16  10  12  17  9  11  16  3d  8  1 0  1 1  7  9  1 3  ------4a  14  17  24  10  15  21  13  17  22  15  17  20  4b  15  19  25  12  17  26  14  17  24  13  18  24  4c  15  22  28  13  16  26  15  20  28  16  21  27  5a  13  14  19  10  13  19  12  13  19  9  13  15  5b  13  16  23  10  13  20  13  14  18  11  14  18  5c  13  20  27  12  16  24  13  16  24  9  15  20  Standard  16  21  29  13  19  31  15  20  32  15  22  29 to the other compounds in the same series. Further, SAR studies revealed that pyrimidine having alkyl or aromatic substitution on sulphur (2a-d, 3a-d) shows less inhibitory antibacterial results. The maximum inhibition was observed in thiazolopyrimidines (4a-c). Also, the synthesized compounds carrying the thiazole ring and 3-nitrophenyl (4c) or 4-hydroxyphenyl (4b) group has shown excellent antibacterial activity as compared to the other derivatives. From the results of antifungal testing of the compounds, 1-5, it has been found that the compounds carrying dimethylated adduct (2a-d) and benzimidazole substituted derivative (5a-c) have shown better activity as compared to the other derivatives. Compared to the compounds 1a-d, dimethylated adduct, 2a-d, have shown better antifungal activity. This may be due to increase in lipophilicity. Better antifungal activity by benzimidazole derivatives may be due to the presence of imidazole moiety in the structure. The in vitro antifungal screening indicated that the presence of 3-nitro substitution to the benzene ring as in compounds, 2c, 5c, 1c, 3c and 4c, increased their inhibitory activities compared to the other compounds in the same series. Dimethylated adduct carrying 3-nitrophenyl (2c) group has shown excellent antifungal activity as compared to the other derivatives. Thus, the nature of substituent on the benzene ring and the heterocyclic skeleton attached to pyrimidine molecules has a strong influence on the extent of antimicrobial activity. 
Conclusion
In conclusion, we have described simple and efficient protocol for the synthesis of pyrimidine derivatives (1) and their thioethers (2-5) with good yields. All the synthesized compounds (1-5) have been investigated for their in vitro antibacterial and antifungal activities. In the newly synthesized compounds, it is clear that the highest antibacterial activity was found in compounds 4c, 4b, 5c and 4a, whereas highest antifungal activity was observed in compounds 2c, 2d and 5c. The structureactivity relationship studies revealed that thiazolopyrimidine derivatives carrying 3-nitrophenyl (4c) or 4-hydroxyphenyl (4b) group have shown highest antibacterial activity, whereas dimethylated adduct carrying 3-nitrophenyl (2c) group on the benzene ring has shown excellent antifungal activity. To summarize, we found that the novel class of pyrimidines and their thioethers has emerged as a valuable lead. Few of the synthesized compounds might be useful as antibacterial and antifungal agents in future. These new pyrimidine derivatives have proved to be promising candidates for further efficacy evaluation.
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